Read by QxMD icon Read

statins with time of dosing

Giuseppe Di Stolfo
BACKGROUND: Carotid stenting stimulates intimal proliferation through platelet and stem cell activation. OBJECTIVE: The aim of this study is to evaluate whether the administration before or after carotid stenting of clopidogrel loading dose may play a role on circulating endothelial progenitor cells, stromal cell-derived factor-1α (SDF-1α) and neointimal hyperplasia. METHODS: We recruited 13 patients (aged 74.52±7.23) with indication of carotid revascularization and in therapy with salicylic acid and statin...
September 29, 2019: Clinical Hemorheology and Microcirculation
Ning Yang, Bo Dong, Jinyu Yang, Yang Li, Lu Kou, Yue Liu, Qin Qin
BACKGROUND: Restenosis after percutaneous coronary intervention in coronary heart disease remains an unsolved problem. Clusterin (CLU) (or Apolipoprotein [Apo] J) levels have been reported to be elevated during the progression of postangioplasty restenosis and atherosclerosis. However, its role in neointimal hyperplasia is still controversial. OBJECTIVE: To elucidate the role Apo J in neointimal hyperplasia in a rat carotid artery model in vivo with or without rosuvastatin administration...
September 21, 2018: Arquivos Brasileiros de Cardiologia
Branislav Vohnout, Ľubomíra Fábryová, Alexander Klabník, Michaela Kadurová, Karin Bálinth, Miriam Kozárová, Ingrid Bugáňová, Jana Sirotiaková, Katarína Rašlová
BACKGROUND AND AIMS: Maximal doses of potent statins are the cornerstone of treatment of familial hypercholesterolemia (FH). Despite this, a substantial proportion of FH patients are either under-treated or not treated at all. The aim of this work was to evaluate, in a retrospective study, the treatment of FH patients, the proportion of FH patients reaching low-density lipoprotein cholesterol (LDL-C) goals, and reasons for not reaching LDL-C goals, in 8 lipid clinics in Slovakia dealing with FH patients...
October 2018: Atherosclerosis
Renato D Lopes, Pedro G M de Barros E Silva, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lilian Mazza Barbosa, Lucas Petri Damiani, Renato Hideo Nakagawa Santos, Ligia Nasi Laranjeira, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, John H Alexander, Christopher B Granger, Otavio Berwanger
Importance: Loading doses of atorvastatin did not show reduction on clinical outcomes in the overall population of patients with acute coronary syndrome (ACS) enrolled in the Statins Evaluation in Coronary Procedures and Revascularization (SECURE-PCI) trial, but a potential benefit was identified in patients who subsequently underwent percutaneous coronary intervention (PCI). Objectives: To determine whether periprocedural loading doses of atorvastatin are associated with decreased 30-day major adverse cardiovascular events (MACE) in patients with ACS undergoing PCI according to type of ACS and timing of atorvastatin administration before PCI...
September 24, 2018: JAMA Cardiology
Tao-Min Huang, Vin-Cent Wu, Yu-Feng Lin, Jian-Jhong Wang, Chih-Chung Shiao, Likwang Chen, Shih-Chieh Jeff Chueh, Eric Chueh, Shao-Yu Yang, Tai-Shuan Lai, Shuei-Liong Lin, Tzong-Shinn Chu, Kwan-Dun Wu
Although statin treatment is recommended for patients with chronic kidney disease (CKD) stages I⁻IV, its potential benefits have not been reported in advanced CKD patients. Non-diabetic patients with advanced CKD (pre-dialysis patients, estimated glomerular filtration rate <15 mL/min/1.73 m²) were enrolled from a National Health Insurance Research Database with a population of 23 million. Statin users and non-users were matched using propensity scoring and analyzed using Cox proportional hazards models, taking mortality as a competing risk with subsequent end-stage renal disease (ESRD) and statin doses as time-dependent variables...
September 17, 2018: Journal of Clinical Medicine
Mohamed Sobhy, Adel El Etriby, Amany El Nashar, Sameh Wajih, Martin Horack, Philippe Brudi, Dominik Lautsch, Baishali Ambegaonkar, Ami Vyas, Anselm K Gitt
Background: Effective management of hyperlipidemia is of utmost importance for prevention of recurring cardiovascular events after an acute coronary syndrome (ACS). Indeed, guidelines recommend a low-density lipoprotein cholesterol (LDL-C) level of <70 mg/dL for such patients. The Dyslipidemia International Study II (DYSIS II) - Egypt was initiated in order to quantify the prevalence and extent of hyperlipidemia in patients presenting with an ACS in Egypt. Methods: In this prospective, observational study, we documented patients presenting with an ACS at either of two participating centers in Egypt between November 2013 and September 2014...
September 2018: The Egyptian heart journal: (EHJ): official bulletin of the Egyptian Society of Cardiology
Anselm K Gitt, Johannes Rieber, Rainer Hambrecht, Johannes Brachmann, Kristof Graf, Martin Horack, Barbara Karmann, Ami Vyas, Dominik Lautsch, Baishali Ambegaonkar, Philippe Brudi
OBJECTIVE: To document utilization of lipid-lowering therapy, attainment of low-density lipoprotein cholesterol target values, and cardiovascular outcomes in patients hospitalized for acute coronary syndrome in Germany. METHODS: The Dyslipidemia International Study II was a multicenter, observational study of the prevalence of dyslipidemia and lipid target value attainment in patients surviving any acute coronary syndrome event. Among patients on lipid-lowering therapy for ≥3 months, use of lipid-lowering therapy and lipid profiles were assessed at admission and again at 120 ± 15 days after admission (the follow-up time point)...
September 3, 2018: Wiener Klinische Wochenschrift
Ramsha Riaz, Aleena Zehra Merchant, Muhammad Salman Ul Haq, Syed Ali Raza Nasir, Yusra Rizvi, Jehanzeb Ahmed Khan, Sara Mohiuddin Zakaria, Hassaan Jawed, Khizar Hamid, Noor-Ul-Ain Zehra, Madiha Ahmed, Hussain Asif Ali, Kaneez Fatima
OBJECTIVE: Statins are widely used drugs, known to cause myalgia, leading to high discontinuation rates. The objective of our study was to determine the frequency of myalgia in patients on everyday-dose (EDD) regimen with those on alternate-day dose (ADD) regimen. METHODS: This cross sectional study was conducted in a tertiary care hospital of Pakistan. A sample size of 400 patients between the age of 40-70 years, taking simvastatin 40mg for at least 6 months or more were selected...
July 2018: Indian Heart Journal
Kaku Nakano, Tetsuya Matoba, Jun-Ichiro Koga, Yushi Kashihara, Masato Fukae, Ichiro Ieiri, Masanari Shiramoto, Shin Irie, Junji Kishimoto, Koji Todaka, Kensuke Egashira
Pulmonary hypertension (PH) is a disease with poor prognosis, caused by the obstruction/stenosis of small pulmonary arteries. Statin is known to have vasodilating and anti-inflammatory property and is considered to be a candidate of therapeutic agents for the treatment of PH, but its efficacy has not been verified in clinical trials. We have formulated pitavastatin incorporating nanoparticles composed of poly (lactic-co-glycolic acid) (NK-104-NP) to improve drug delivery to the pulmonary arteries and evaluated their safety and pharmacokinetics in healthy volunteers...
September 26, 2018: International Heart Journal
Yewon Choi, SeungHwan Lee, In-Jin Jang, Kyung-Sang Yu
Introduction: Major cardiovascular risk factors, including hypertension and dyslipidemia, are often comorbidities, frequently leading to concurrent prescription of angiotensin receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). The study's objective was to evaluate the effect of coadministration of fimasartan and atorvastatin on their pharmacokinetics (PKs). Subjects and methods: In a randomized, open-label, three-period, six-sequence, crossover, multiple-dose study, 36 healthy subjects received 120 mg fimasartan, 40 mg atorvastatin, or both (based on their assigned sequence) once daily for 7 days in each period, with a 7-day washout between periods...
2018: Drug Design, Development and Therapy
Tamara R Nikolic Turnic, Vladimir Lj Jakovljevic, Dragan M Djuric, Nevena S Jeremic, Jovana N Jeremic, Isidora M Milosavljevic, Ivan M Srejovic, Dragica V Selakovic, Vladimir I Zivkovic
The aim of this study was to assess the impact of atorvastatin and simvastatin on myocardial contractility during the different degrees of hyperhomocysteinemia (HHcy) in rats. Study was conducted on adult male Wistar albino rats (n = 90; 4 weeks old; 100 ± 15 g body mass) in which HHcy was achieved by dietary manipulation. Animals were exposed to pharmacology treatment with atorvastatin in dose of 3 mg/kg per day i.p. or simvastatin in dose of 5 mg/kg per day i.p. at the same time every day, according to equivalent therapeutic doses of these statins (10 mg atorvastatin = 20 mg simvastatin)...
October 2018: Canadian Journal of Physiology and Pharmacology
Florine Tissier, Firas Farhat, Clothilde Philouze, Jean-Claude Desfontis, Romain Didier, Martine Gilard, M Yassine Mallem, Jacques Mansourati, Christine Moisan, Karine PIchavant-Rafini, Michael Theron, Aline Amérand
Statins are currently used in prevention of cardiovascular diseases in high risk populations, and could be considered in primary prevention. However, few studies are available on the long-term effects of low-doses of statins, especially on mitochondrial function and ROS (Reactive Oxygen Species) metabolism at cardiac level. This study aimed to determine potential effects of a long-term atorvastatin treatment, at low-dose concentration, on the myocardium mitochondrial respiration. 34 Watanabe rabbits were treated or not with atorvastatin (2...
July 16, 2018: Canadian Journal of Physiology and Pharmacology
Junyu Zhao, Chunmei Xu, Jinming Yao, Changzhen Yu, Lin Liao, Jianjun Dong
BACKGROUND/AIMS: Experimental studies have reported the antineoplastic effects of statins in thyroid carcinoma; however, observational studies suggested that statins might increase the risk of thyroid carcinoma. Therefore, this study evaluated the antineoplastic effects of statins in both in vitro studies and animal models, as well as the epidemiological evidence. METHODS: Databases-PubMed, Cochrane Library, SinoMed, CNKI, Wanfang, and clinical trial registries- were searched...
2018: Cellular Physiology and Biochemistry
Gaetano M De Ferrari, Gian P Perna, Antonino Nicosia, Luigina Guasti, Gavino Casu, Claudio Cuccia, Francesca Picco, Caterina Strazzella, Rossana Totaro, Stefania Cercone, Laura Canullo, Martin Horack, Dominik Lautsch, Anselm K Gitt, Matteo Di Biase
AIMS: The analysis evaluated the contemporary percentage of patients with established coronary heart disease (CHD) reaching the European guidelines recommended LDL-cholesterol (LDL-C) levels of less than 70 mg/dl and the threshold required for proprotein convertase subtlisin/kexin type 9 reimbursement in Italy (100 mg/dl). It also assessed how these percentages would change in case of diffuse use of ezetimibe. METHODS: The Dyslipidemia International Study II enrolled CHD patients aged at least 18 either on lipid-lowering therapy (LLT) for at least 3 months or not on LLT at the time of the lipid profile...
September 2018: Journal of Cardiovascular Medicine
E O Vershinina, A N Repin, M S Timofeev, V V Udut
PURPOSE OF THE STUDY: To compare the effect of loading doses of atorvastatin and rosuvastatin on the value of the acute kidney injury and acute inflammatory response to elective percutaneous coronary interventions. MATERIALS AND METHODS: An open prospective comparative study included 68 patients referred for elective percutaneous coronary intervention (PCI). At baseline, all patients had been taking statins for a long time as a standard lipid-lowering therapy. The first group included 33 patients who received a loading dose of 80 mg of atorvastatin (As) 12 hours before the intervention with saving this dose for 2-6 days...
2018: Kardiologiia
Susana Barros, Rosa Montes, José Benito Quintana, Rosario Rodil, Ana André, Ana Capitão, Joana Soares, Miguel M Santos, Teresa Neuparth
Simvastatin (SIM), a hypocholesterolaemic compound, is among the most prescribed pharmaceuticals for cardiovascular disease prevention worldwide. Several studies have shown that acute exposure to SIM causes multiple adverse effects in aquatic organisms. However, uncertainties still remain regarding the chronic effects of SIM in aquatic ecosystems. Therefore, the present study aimed to investigate the effects of SIM in the model freshwater teleost zebrafish (Danio rerio) following a chronic exposure (90 days) to environmentally relevant concentrations ranging from 8 ng/L to 1000 ng/L...
August 2018: Aquatic Toxicology
Joël Coste, Cécile Billionnet, Annie Rudnichi, Jacques Pouchot, Rosemary Dray-Spira, Philippe Giral, Mahmoud Zureik
Aims The purpose of this study was to investigate the risk of rhabdomyolysis in subjects initiating statin therapy for primary prevention of cardiovascular disease, focusing on the type of statin, dose and time since initiation. Methods and results A nationwide cohort study using French hospital discharge and claims databases was performed, studying subjects from the general population 40-75 years in 2009, with no history of cardiovascular disease and no lipid-lowering drugs during the preceding three-year period, followed for up to seven years...
January 1, 2018: European Journal of Preventive Cardiology
Kamal Awad, Maciej Banach
PURPOSE OF REVIEW: In humans, cholesterol biosynthesis varies diurnally, reaching its peak at night. Therefore, choosing the time of statin administration is critical because of their different half-lives. Dose timing becomes more important in patients with polypharmacy because it might affect their adherence to the statin therapy. RECENT FINDINGS: Herein, we narratively summarized the available clinical studies (n = 17) and meta-analyses (n = 2) that compared the morning with the evening dose of statins in terms of safety and efficacy, with special focus on their low-density lipoprotein-lowering effects...
August 2018: Current Opinion in Lipidology
Peter Ihle, Franz-Werner Dippel, Ingrid Schubert
Aim of the study was to assess the incidence of statin-associated myopathy (SAM) under real-life conditions in Germany. DATABASE: Administrative data (master data, diagnoses, prescriptions) for all individuals in Germany insured with the Statutory Health Insurance. Basic population: individuals 18 years and older who have been insured continually from 2009 to 2011 (52.9 million; 29.9 million men, 23.9 million women). Data access is provided by the German Institute of Medical Documentation and Information, DIMDI) according to the Data Transparency Regulation of 2012...
June 2018: Pharmacology Research & Perspectives
Samira Salihovic, Jordan Stubleski, Anna Kärrman, Anders Larsson, Tove Fall, Lars Lind, P Monica Lind
BACKGROUND: While it is known that perfluoroalkyl substances (PFASs) induce liver toxicity in experimental studies, the evidence of an association in humans is inconsistent. OBJECTIVE: The main aim of the present study was to examine the association of PFAS concentrations and markers of liver function using panel data. METHODS: We investigated 1002 individuals from Sweden (50% women) at ages 70, 75 and 80 in 2001-2014. Eight PFASs were measured in plasma using isotope dilution ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS)...
August 2018: Environment International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"